Year-end report April 2019 – March 2020
CEO’s comments We continue to show a strong growth with sales increasing by 45 percent for the 2019/20 financial year compared with the previous year and a 29 percent growth for the quarter. Sales for the totalled SEK 18.9 million for the quarter, our second strongest quarter ever, and SEK 72 million for the year. The gross margin for the quarter fell to 47 percent due to a product mix with large sales of, amongst others, Paracetamol, a product with several competitors, which is therefore sold at a lower margin.The quarter has been marked by the Covid-19 pandemic as the company has its